[CITATION][C] Breast cancer—loss of PTEN predicts resistance to treatment
PP Pandolfi - New England Journal of Medicine, 2004 - Mass Medical Soc
New England Journal of Medicine, 2004•Mass Medical Soc
A new study uncovers a mechanism by which trastuzumab (Herceptin) counters the
progression of cancer. The findings point to a subgroup of patients who are likely to have a
response to treatment.
progression of cancer. The findings point to a subgroup of patients who are likely to have a
response to treatment.
A new study uncovers a mechanism by which trastuzumab (Herceptin) counters the progression of cancer. The findings point to a subgroup of patients who are likely to have a response to treatment.
The New England Journal Of Medicine